Freitag, 5. März 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

PROTECT Protein-rich Nutritional Therapy Combined With Time-efficient Exercise in Cancer Therapy

Rekrutierend

NCT-Nummer:
NCT04065815

Studienbeginn:
Mai 2019

Letztes Update:
22.08.2019

Wirkstoff:
-

Indikation (Clinical Trials):
Wasting Syndrome, Inflammation, Cachexia

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University of Erlangen-Nürnberg Medical School, University of Erlangen-Nürnberg Medical School

Collaborator:
-

Studienleiter

Dejan Reljic, Dr.
Principal Investigator
University Erlangen Nuremberg Medical School
Yurdagül Zopf, Prof.
Principal Investigator
University Erlangen Nuremberg Medical School

Kontakt

Studienlocations (1 von 1)

Department of Medicine 1, Hector-Center for Nutrition, Exercise and Sports
91054 Erlangen
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Hans Joachim Herrmann, Dr.
Phone: +49 9131 8545218
E-Mail: hans.herrmann@uk-erlangen.de

Dejan Reljic, Dr.
Phone: +49 9131 8545218
E-Mail: dejan.reljic@uk-erlangen.de
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

This study aims to evaluate the effects of a 12-week protein-rich individualized nutritional therapy combined with different time-efficient exercise programs on overall physical fitness (cardiorespiratory fitness and muscular fitness), inflammation, and muscle mass/body composition in patients with malignant disease undergoing curative or palliative anti-cancer treatment
 

Ein-/Ausschlusskriterien

Inclusion Criteria:

- malignant disease (solid or hematological cancer): head and neck cancer, colorectal carcinoma, small intestinal cancer, gastric cancer, oesophageal cancer, pancreas carcinoma, liver cell carcinoma, cholangiocarcinoma, lung cancer, breast cancer, cervix cancer, ovarian cancer, prostate cancer, renal cell carcinoma, malignant melanoma, patients with leukaemia and malignant lymphomas or Graft-versus-Host-Disease after bone marrow transplantation

- ongoing or planned curative or palliative anti-cancer therapy

- ECOG-Status 0-2

Exclusion Criteria:

- simultaneous participation in other nutritional or exercise intervention Trials

- bone metastases with high fracture risk

- cardiovascular disease

- use of anabolic medications

- epilepsy

- severe neurological or rheumatic diseases

- skin lesions in the area of electrodes

- energy active metals in body

- pregnancy

- acute vein thrombosis

Studien-Rationale

Primary outcome:

1. Overall physical fitness (Time Frame - 12 weeks):
Cardiorespiratory Fitness and Muscular Fitness (Overall Fitness Score is calculated from Maximum Oxygen uptake, VO2max, and Muscle strength (estimated from the 1-repetition Maximum - the maximum amount of weight [kg] that can be lifted for one repetition) of the five major muscle groups (chest, upper back, lower back, abdominals, legs)



Secondary outcome:

1. Muscle mass (Time Frame - 12 weeks):
Muscle mass (kg) is assessed by bioelectrical impedance Analysis (BIA)

2. Fat mass (Time Frame - 12 weeks):
Fat mass (kg) is assessed by bioelectrical impedance Analysis (BIA)

3. Total Body Water (Time Frame - 12 weeks):
Total Body Water (L) is assessed by bioelectrical impedance Analysis (BIA)

4. Patient-reported performance status-1 (Time Frame - 12 weeks):
Patient-reported performance Status will be assessed using the ECOG Performance Status questionnaire. It describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability. The score ranges from 0-5 (lower values = better outcome).

5. Patient-reported performance status-2 (Time Frame - 12 weeks):
Patient-reported performance status-2 will be assessed using the Karnofsky index. It is used methods to assess the functional status of a Patient. The score ranges from 0-100 (higher value = better outcome).

6. Patient-reported Quality of Life (QoL) (Time Frame - 12 weeks):
Patient-reported QoL will be assessed using the EORTC QLQ-C30 questionnaire. It contains 30 questions (items), representing various aspects/dimensions of QoL (physical, role, emotional, cognitive and social), and 3 symptom scales (fatigue, pain and nausea).The scales of the different dimensions of QoL (higher values = better outcome) and symptoms (lower values = better outcomes) range from 0-100.

7. Patient-reported Fatigue (Time Frame - 12 weeks):
Fatigue will be assessed using the FACIT-Fatigue scale. It contains 13 items (different aspects/dimensions of fatigue) each assessed on a scale of 0-4, with lower values indicating a better outcome).

8. Patient-reported Physical Activity (Time Frame - 12 weeks):
Patient-reported Physical Activity (PA) will be assessed using the the International Physical Activity Questionnaire (IPAQ). IPAQ records 4 aspects of PA (job-, transportation-, housework-, and leisure-time-related). There are two forms of output from scoring the IPAQ. Results can be reported in categories (low, moderate or high PA levels) or as a continuous variable (MET minutes a week, 1 MET = resting energy expenditure). MET minutes represent the amount of energy expended carrying out physical activity. High PA = at least 1500 MET minutes/week; moderate PA: at least 600 MET minutes/week; low PA: < 600 MET minutes/week. Higher values represent a better outcome.

9. Objective Physical Activity (Time Frame - 12 weeks):
Objective measurement of physical activity will be preformed using Pedometers. Higher values represent a better outcome.

10. Inflammatory blood markers (Time Frame - 12 weeks):
Inflammation will be assessed by measuring blood levels (mg/L) of c-reactive protein (CRP) and high-sensitivity creactive protein (hs-CRP).

11. Cardiometabolic Risk Profile (Metabolic Syndrome Z-Score, MetS) (Time Frame - 12 weeks):
MetS will be calculated MetS-Z-Score will be calculated from each individual's measures of waist circumference (cm), mean arterial blood pressure (mmHg), blood levels of glucose (mg/dL), triglycerides (mg/dL), and HDL-cholesterol (mg/ dL), based on equations specific to sex.

Studien-Arme

  • Experimental: Resistance Training (RT)
    Individualized, protein-rich nutritional therapy combined with resistance training
  • Experimental: WB-EMS
    Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
  • Experimental: High-intensity interval training (HIIT)
    Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
  • Experimental: Combined HIIT and Resistance Training (Combi)
    Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training

Geprüfte Regime

  • Resistance Training:
    Conventional Resistance Training: Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs) 1 set per exercise time-effort per session: ~20 min 2 training sessions per week
  • WB-EMS:
    Whole-Body Electromyostimulation (WB-EMS): Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training: Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial time-effort per session: ~20 min 2 training sessions per week
  • High-intensity interval training (HIIT):
    HIIT: Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT): supervised cycle-ergometer training at at 80-95% HRmax time-effort per session: ~15 min 2 training sessions per week
  • Combined HIIT and Resistance Training (Combi):
    HIIT combined with conventional Resistance Training: Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program: HIIT: supervised cycle-ergometer training at at 80-95% HRmax time-effort per session: ~15 min 1 training session per week Resistance Training: five exercises: exercises (chest, upper/lower back, abdominals, legs) 1 set per exercise time-effort per session: ~20 min 1 training session per week

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Heller Hautkrebs: Signalweg entschlüsselt

Beim Hautkrebs gibt es verschiedene Krankheitsformen: Mit Abstand am häufigsten ist dabei das so genannte Basalzellkarzinom, eine Form von hellem Hautkrebs, bei der sich der Tumor von seinem Entstehungsort in der Haut langsam aber stetig ausbreitet. Zwar bildet das Basalzellkarzinom im Allgemeinen keine Tochtergeschwülste (Metastasen), der Tumor sollte jedoch so früh wie möglich behandelt werden, da er ansonsten das umgebende Gewebe zerstören und sogar Muskeln...

Weltkrebstag: Deutsche Krebshilfe informiert und ruft zum Handeln auf

Weltkrebstag: Deutsche Krebshilfe informiert und ruft zum Handeln auf
© julief514 / Fotolia.com

Am 4. Februar ist Weltkrebstag. Das diesjährige Motto der Weltgesundheitsorganisation lautet: „Wir können. Ich kann.“ Es steht dafür, dass Menschen durch einen gesunden Lebensstil dazu beitragen können, vielen Krebsarten vorzubeugen. „Gesundheit ist ein hohes Gut und es macht Spaß etwas dafür zu tun“, betont Gerd Nettekoven, Vorstandsvorsitzender der Deutschen Krebshilfe. Die Organisation bietet Interessierten kostenlose Infomaterialien...